RU58841 10mg/ml – 20ml (PSK-3841/HMR-3841) – Peptide Infused Sodium Hyaluronate (HA) Serum Information

Product Results – RU58841 10mg/ml – 20ml : Inhibits the hair-thinning effects of DHT (dihydrotestosterone). It increases the percentage of hair growth in the anagen phase. It improves hair density and diameter. Topically applied to increase hair growth

Strength – 10MG/ml peptide serums containing the optimal amount of Hyaluronic Acid at 2% potency, balanced between 4 and 5 pH.

Ingredients : 10mg/ml RU58841 peptide, 10ml Sodium Hyaluronate (HA) serum (overall concentration – 2%/ml) balanced to 4 – 5 pH, 1.1%/20ml preservative – Ascorbic Acid, 10ml bacteriostatic water (0.9%/ml Benzyl Alcohol), free of Paraben (parahydroxybenzoates esters | parahydroxybenzoic acid)

Introduction – RU58841 10mg/ml – 20ml

A study on regenerative medicine says that Hyaluronic Acid mixed with anti aging, collagen peptides can speed up the healing process and make the healing tissue better overall. Other research says that hyaluronic acid can help wounds heal faster by making them more hydrated, reducing inflammation, and encouraging the growth of new blood vessels. RU58841 is a non-steroidal anti-androgenic medication that was initially developed in the 1980s as a topical treatment remedy for acne and male pattern baldness – androgenetic alopecia. RU58841 goes by several names. It is also known as PSK3841 or HMR3841. It was renamed after newer companies bought the rights to the original product, RU58841.

The concept of RU58841 is quite old. The idea to develop it was first put forth by a French pharmaceutical company called Roussel Uclaf, way back in the 1970s. Although it had been produced in the 80s, most of the research about its development progressed into the 90s.

The main aim of these scientists was to develop a potent medication that would effectively manage acne and androgenic alopecia when applied topically while avoiding/limiting systemic side effects that are commonly observed with other anti-androgens. Rats and hamsters were the animal models used to test its effectiveness. During the trial phase of the mediation, the RU58841 results were very promising.

Actually, even small doses as low as 0.001 milligrams showed significant local effects. Even at high doses of up to 0.01 milligrams, the action was still limited to the site of application – a much-desired relief for the researchers.

A lot has transpired since the inception of the idea. For instance, several companies had acquired and dropped their right to this product. Eventually, one company – ProStraken – acquired the full rights to RU58841 and changed its name to PSK3841.

They conducted two human clinical trials (a phase 1 and a phase 2 trial). The phase 1 trial involved the application of 5% solution twice daily for 4 weeks, and the phase 2 trial compared the placebo to 2.5% and 5% solutions of RU58841 for 6 months. Although the results were apparently good and well tolerated, none of these were ever published.

Prostraken decided to conduct a phase 3 trial as well, but this never went ahead. The company was acquired by a Japanese company called Kyowa Kurin, after which the project got canceled for monetary reasons.

Since then, similar studies on humans have not been conducted or published in peer-reviewed medical journals. A few monkey-based studies have been done, which determined the optimal dosing of RU58841 to be 5%, and one study compared it against finasteride. The monkeys experienced an increase in hair growth of 103%, compared to just 88% for those given finasteride. The finasteride group had serum DHT levels lowered by 70%, while the RU58841 group had no change in levels.

Another study evaluated the effectiveness of RU58841 on human hair transplanted onto the skin of nude mice. However, as there have been no direct human studies for more than a decade, the FDA has not approved it for the management of any condition. Since this medication is anti-androgen, it may be able to target androgen-dependent skin conditions such as acne and androgenic alopecia. Right now, you are probably aware that hair loss occurs due to the action of DHT on the hair follicles.

Other anti-androgenic drugs act by either reducing or blocking the synthesis of dihydrotestosterone (DHT). The mechanism of RU58841 is entirely different from other anti-androgenic medications. Here is the reason: RU58841 competitively binds to the receptors of DHT. So, it actually blocks DHT from attaching itself to the receptors. It does not reduce the production of DHT. As a result, the systemic side effects that occur due to lowered production of DHT are not seen, for example, sexual side effects.

Just like finasteride (but minus the side effects), the effects of RU58841 are as follows: